Physician profile
Daniel Cepin
NPI 1053320556
$8,272.82
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,937 · 2020: $1,289 · 2021: $1,921 · 2022: $1,119 · 2023: $1,554 · 2024: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $823.06 | 2019-2023 | Aveir |
| Novartis Pharmaceuticals Corporation | $800.96 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $739.80 | 2019-2024 | Xarelto |
| Biotronik INC. | $672.56 | 2019-2022 | |
| Medtronic Vascular, INC. | $579.09 | 2019-2020 | |
| Boston Scientific Corporation | $537.58 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $532.53 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $422.05 | 2019-2023 | Brilinta |
| Merck Sharp & Dohme LLC | $341.64 | 2021-2024 | Verquvo |
| Philips North America LLC | $335.65 | 2020 | |
| Pfizer INC. | $272.94 | 2019-2024 | |
| Amgen INC. | $243.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.73 | 2019-2024 | Jardiance |
| Braemar Manufacturing, LLC | $216.18 | 2019 | |
| Shockwave Medical, INC | $177.62 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $169.77 | 2019-2024 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals, Ltd. | $169.37 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $164.75 | 2023 | Amvuttra |
| Edwards Lifesciences Corporation | $138.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $135.00 | 2023 | |
| Medtronic, INC. | $113.41 | 2021-2024 | Plasmablade(Tm) |
| Cvrx, INC. | $98.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $80.71 | 2019-2024 | |
| Chiesi USA, INC. | $49.21 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $39.32 | 2022 | |
| Abiomed | $32.10 | 2022 | |
| Atricure, INC. | $25.21 | 2022 | |
| Recor Medical INC | $24.96 | 2024 | Paradise Renal Denervation System |
| Irhythm Technologies, INC. | $23.40 | 2022 | |
| Allergan, INC. | $22.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.69 | 2019 | |
| Bardy Diagnostics, INC. | $19.00 | 2021 | |
| Baxter Healthcare | $17.18 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $16.63 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cepin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.